

~~12-13.~~ CANCEL

Please add the following claims:

35. The method of claim 1, wherein the dosage is at least 40 mg/kg body weight per week.

36. The method of claim 1, further comprising detecting a reduction in hypertrophic cardiomyopathy responsive to the administering.

37. The method of claim 1, further comprising detecting increased alpha-glucosidase activity in muscle responsive to the administering.

38. The method of claim 1, wherein the human alpha-glucosidase is administered to a population of patients with infantile Pompe's disease and at least 50% survive more than six months post diagnosis of the infantile Pompe's disease without life-saving intervention.

Remarks

Support for the amendment to claim 1 is provided by claims 2 and 10. The paragraph numbering of the office action is used in responding to the Examiner's comments.

4. A sequence listing is attached.

6. Claims 1-2, 6-10, 12, 14 and 15 stand rejected as anticipated by Kikuchi. Kikuchi is said to disclose administering human acid alpha glucosidase to quail at a dosage of 14 mg/kg body weight. Kikuchi is also said to disclose that such treatment results in normal histopathology of the heart and liver. This rejection is respectfully traversed, particularly as applied to the amended claims for the following reasons.